Viatris Inc (VTRS): Results of Operations and Financial Condition
Viatris Inc (VTRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Viatris Reports Second-Quarter 2026 Financial Results • Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million • Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025 •
How this was made
The 30-second read
Why it matters
Traders can update models using the disclosed Q2 revenue, Adjusted EBITDA, free cash flow, leverage ratio, and the stated guidance midpoint increases, while also accounting for GAAP distortions from the Tyrvaya rights sale-related non-cash charge.
Market read
A same-day earnings and guidance update with balance-sheet and capital-allocation actions provides a concrete catalyst for repricing VTRS expectations.
What to watch
Investors may focus on whether the new-product revenue trajectory ($450M to $550M expected for 2026) is sufficient to sustain the guidance raise, and how ARV supply constraints in Emerging Markets evolve.
Viatris Reports Second-Quarter 2026 Financial Results
Total Revenues grew 5% on a reported basis, Adjusted EBITDA grew 10% on a reported basis, and the Company raised 2026 financial guidance midpoints for all metrics, while U.S. GAAP net loss widened to $ (118.8) million and second-half supply disruption risk was identified.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total Revenuesother | $ 3,756.8 | – | 5% reported; 4% operational |
| Total Net Salesother | $ 3,745.9 | – | 5% reported; 4% operational |
| U.S. GAAP Gross ProfitGAAP | $ 1,456.5 | – | 9% |
| U.S. GAAP Gross MarginGAAP | 38.8 % | – | – |
| Adjusted Gross Profitnon-GAAP | $ 2,158.9 | – | 6% |
| Adjusted Gross Marginnon-GAAP | 57.5 % | – | – |
| U.S. GAAP Net LossGAAP | $ (118.8) | – | NM |
| U.S. GAAP Loss Per ShareGAAP | $ (0.10) | – | NM |
| Adjusted Net Earningsnon-GAAP | $ 808.5 | – | 11% |
| Adjusted EPSnon-GAAP | $ 0.69 | – | 11% reported; 9% operational |
| EBITDAnon-GAAP | $ 729.0 | – | 26% |
| Adjusted EBITDAnon-GAAP | $ 1,188.3 | – | 10% reported; 8% operational |
| U.S. GAAP Net Cash Provided by Operating ActivitiesGAAP | $ 381.8 | – | 74% |
| Capital Expendituresother | 52.8 | – | —% |
| Free Cash Flownon-GAAP | $ 329.0 | – | 97% |
| Free Cash Flow excluding transaction-related and restructuring-related costsnon-GAAP | $449 million | – | – |
| Six Months Total Revenuesother | $ 7,273.8 | – | 6% reported; 3% operational |
| Six Months Total Net Salesother | $ 7,255.6 | – | 7% reported; 3% operational |
| Six Months U.S. GAAP Gross ProfitGAAP | $ 2,613.7 | – | 5% |
| Six Months U.S. GAAP Gross MarginGAAP | 35.9 % | – | – |
| Six Months Adjusted Gross Profitnon-GAAP | $ 4,129.2 | – | 7% |
| Six Months Adjusted Gross Marginnon-GAAP | 56.8 % | – | – |
| Six Months U.S. GAAP Net Earnings (Loss)GAAP | $ 57.6 | – | NM |
| Six Months U.S. GAAP Earnings (Loss) Per ShareGAAP | $ 0.05 | – | NM |
| Six Months Adjusted Net Earningsnon-GAAP | $ 1,502.6 | – | 13% |
| Six Months Adjusted EPSnon-GAAP | $ 1.28 | – | 15% reported; 11% operational |
| Six Months EBITDAnon-GAAP | $ 1,277.9 | – | NM |
| Six Months Adjusted EBITDAnon-GAAP | $ 2,237.8 | – | 12% reported; 9% operational |
| Six Months U.S. GAAP Net Cash Provided by Operating ActivitiesGAAP | $ 770.1 | – | 2% |
| Six Months Capital Expendituresother | 92.7 | – | (3)% |
| Six Months Free Cash Flownon-GAAP | $ 677.4 | – | 3% |
| Six Months Free Cash Flow excluding transaction-related and restructuring-related costsnon-GAAP | $908 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Developed MarketsNew product sales in Developed Markets. | 2,193.7 | – | 4% reported; 2% operational |
| Emerging MarketsBrands net sales reflect continued strength in Emerging Markets; Generics net sales were partially offset by supply constraints in the ARV business within Emerging Markets. | 542.3 | – | (2)% reported; (2)% operational |
| JANZNot separately specified in the supplied text. | 296.1 | – | (3)% reported; —% operational |
| Greater ChinaStrong growth in Greater China. | 713.8 | – | 21% reported; 16% operational |
| BrandsContinued strength in Greater China and Emerging Markets. | $ 2,418.4 | – | 6% reported; 4% operational |
| GenericsContributions from new product launches and growth in certain products in Developed Markets, partially offset by supply constraints in the ARV business within Emerging Markets. | 1,327.5 | – | 3% reported; 3% operational |
full-year 2026 outlook
- NoteU.S. GAAP net cash provided by operating activities: between $1.9 billion and $2.1 billion, with a midpoint of approximately $2.0 billion.
- NoteNew product revenues: approximately $450 million to $550 million.
- NoteImpact of product supply disruptions to total revenues in the second half of 2026: between $100 million and $150 million.
- NoteThe Company raised 2026 Financial Guidance Midpoints for All Metrics.
Capital returns
- Through August 5, 2026, the Company has returned approximately $550 million of capital to shareholders.
- Approximately $270 million through share repurchases at a weighted average purchase price of $16.42 per share.
- The Company has approximately $730 million remaining under its existing board-authorized share repurch
What drove it
- Total revenues were primarily driven by new product sales in Developed Markets and strong growth in Greater China.
- The Company generated approximately $101 million in new product revenues and approximately $172 million for the year.
- Adjusted EBITDA growth reflected continued strong operational execution.
- The U.S. FDA approved Gwyn Lo TM in July, and the Company expects Gwyn Lo to be commercially available later this year.
- The FDA approved generic ferric carboxymaltose injection in three strengths: 750 mg/15 mL, 1000 mg/20 mL and 100 mg/2 mL.
- Positive top-line Phase 3 results were announced for VR-205 (targeted-release budesonide formulation) (Nefecon ® ) in Japanese adult patients with primary immunoglobulin A nephropathy at risk of developing end-stage renal disease.
Concerns
- U.S. GAAP net loss was $ (118.8) million compared to $ (4.6) million in the second quarter of 2025.
- The second-quarter 2026 loss was primarily driven by a non-cash charge of $177.8 million related to the planned sale of the product rights for Tyrvaya ® and the write down of that intangible asset to fair value, less cost to sell.
- Supply constraints in the ARV business within Emerging Markets partially offset Generics net sales growth.
- The Nashik, India facility remediation plan is ongoing and has led to intermittent disruptions.
- The temporary manufacturing suspension following a February fire at the Nashik facility, together with intermittent disruptions, is expected to impact product supply in the second half of the year.
- The Company anticipates the impact of product supply disruptions to be between $100 million and $150 million to total revenues in the second half of 2026.
What to watch
- Delivery of approximately $450 million to $550 million in new product revenues in full-year 2026.
- The expected second-half impact of Nashik product supply disruptions of between $100 million and $150 million to total revenues.
- Commercial availability of Gwyn Lo TM later this year.
- The PDUFA goal date of December 27, 2026 for MR-107A-02.
- Completion of the Tyrvaya transaction, which includes an upfront payment of $30 million and an additional $70 million in commercial contingent milestone payments.
- Execution against full-year U.S. GAAP net cash provided by operating activities guidance of between $1.9 billion and $2.1 billion.
Balance sheet and cash flow
- Reduces Gross Leverage Ratio to 2.9x.
- U.S. GAAP net cash provided by operating activities was $381.8 million for the three months ended June 30, 2026.
- Free Cash Flow was $329.0 million for the three months ended June 30, 2026.
- U.S. GAAP net cash provided by operating activities was $770.1 million for the six months ended June 30, 2026.
- Free Cash Flow was $677.4 million for the six months ended June 30, 2026.
- In July, the Company completed the sale of its equity position in Biocon Limited for a pre-tax total consideration of approximately $380 million.
- The sale completes the Company’s monetization of its stake in Biocon Biologics Limited for a total of approximately $780 million.
Analysis
Viatris reported second-quarter Total Revenues of $ 3,756.8 million, up 5% on a reported basis and 4% on an operational basis. Total Net Sales were $ 3,745.9 million, also up 5% reported and 4% operational. Growth was primarily driven by new product sales in Developed Markets and strong growth in Greater China. Greater China net sales rose 21% reported and 16% operational, while Developed Markets grew 4% reported and 2% operational. Emerging Markets and JANZ declined on both reported and operational measures shown in the release.
Management, verbatim
Our second-quarter results reflect another quarter of strong execution and reinforce the momentum we're building across our business.
Scott A. Smith, CEO, Viatris
We delivered another strong quarter of Total Revenues and Adjusted EBITDA growth over the prior year, reflecting continued strong operational execution.
Paul Campbell, Interim CFO, Chief Accounting Officer & Corporate Controller, Viatris
Not in the filing
stated, not guessed- Complete 2026 financial guidance ranges and midpoints for revenue, adjusted EBITDA, adjusted EPS, and other raised metrics were not included in the supplied filing text.
- Prior outlook was not provided.
- U.S. GAAP operating income or loss was not provided in the supplied filing text.
- Operating expenses were not provided in the supplied filing text.
- Tax rate was not provided in the supplied filing text.
- Cash balance was not provided in the supplied filing text.
- Debt balance was not provided in the supplied filing text.
- Dividend amount and dividend per share were not provided in the supplied filing text.
- Prior-quarter comparisons were not provided for the reported metrics.
- The supplied filing text is truncated in the share-repurchase authorization disclosure.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is Viatris’ SEC Form 8-K (Item 2.02) reporting Q2 2026 financial results and updated 2026 financial guidance midpoints, with capital return and a Tyrvaya rights transaction.
Ticker impact
Viatris reported Q2 2026 results and raised 2026 guidance midpoints, alongside a Tyrvaya rights sale and $550M capital return.
Bias upward on guidance raise and EBITDA/free-cash-flow strength, with some offset from the GAAP net loss tied to the Tyrvaya rights sale accounting.
The filing discloses specific Q2 revenue, Adjusted EBITDA, free cash flow, leverage reduction to 2.9x, and explicit guidance midpoint increases, all of which are direct valuation inputs.
Market effects
Signals improving execution and cash generation in large global pharma, potentially supporting sentiment toward generic and branded-mix peers.
Greater China growth cited as a driver may reinforce regional demand optimism for multinational pharma operators.
Guidance raise and leverage reduction can influence broader healthcare large-cap risk appetite, though impact is company-specific.
Counterpoint
GAAP net loss widened due to non-cash charges tied to the Tyrvaya rights sale, so the headline earnings quality may be weaker than Adjusted metrics suggest.
Key entities
- issuerViatris Inc
Reported Q2 2026 results, raised 2026 guidance midpoints, reduced gross leverage to 2.9x, and announced sale of global rights to Tyrvaya plus ~$550M capital return.
- product_rightsTyrvaya
Viatris announced a sale of global rights; the filing notes a non-cash GAAP charge related to planned sale and fair-value write-down.
- pipeline_assetGwyn Lo TM
The release cites U.S. FDA approval as a key pipeline milestone.
